The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trial Selector

Geo Regions

Binimetinib
Encorafenib

Phase 2

Presentation Binimetinib

Encorafenib + Binimetinib

Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8

Phase 2

NCT04511013

Go to page Encorafenib + Binimetinib Binimetinib
Presentation Binimetinib

Encorafenib + Binimetinib

Melanoma

Phase 2

NCT05926960

Go to page Encorafenib + Binimetinib Binimetinib

Phase 3

Presentation Binimetinib

Encorafenib + Binimetinib

Melanoma

Phase 3

NCT04657991

Go to page Encorafenib + Binimetinib Binimetinib

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of January 30, 2024.

*Vepdegestrant is being co-developed with Arvinas Estrogen Receptor, Inc.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.